Cariprazine in the treatment of acute mania in bipolar i disorder: A double-blind, placebo-controlled, Phase III trial

Journal of Affective Disorders

Volumn 174, Issue , 2015, Pages 296-302

  Sachs, Gary S ^a   Greenberg, William M ^b   Starace, Anju ^b   Lu, Kaifeng ^b   Ruth, Adam ^c   Laszlovszky, István ^d   Németh, György ^d   Durgam, Suresh ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Prescott Medical Communications Group   (United States)

^d GEDEON RICHTER LTD   (Hungary)

Author keywords

Antipsychotic; Bipolar disorder; Cariprazine; Dopamine D3 receptors; Mania; Remission

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARIPRAZINE; PLACEBO; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AGED; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIXED MANIA AND DEPRESSION; NAUSEA; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RESTLESSNESS; SOMNOLENCE; SUICIDAL IDEATION; TREMOR; VOMITING; YOUNG MANIA RATING SCALE; ACUTE DISEASE; AKATHISIA, DRUG-INDUCED; BIPOLAR DISORDER; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSPEPSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREMOR; VOMITING;

EID: 84919622725     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.11.018     Document Type: Article

References (37)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders fourth ed. 2000 American Psychiatric Association Washington, DC (text revision)
2. T.R. Barnes A rating scale for drug-induced akathisia Br. J. Psychiatry 154 1989 672 676
3. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron Akt/GSK3 signaling in the action of psychotropic drugs Annu. Rev. Pharmacol. Toxicol. 49 2009 327 347
4. J.M. Beaulieu, E. Tirotta, T.D. Sotnikova, B. Masri, A. Salahpour, R.R. Gainetdinov, E. Borrelli, and M.G. Caron Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo J. Neurosci. 27 2007 881 885
5. Calabrese, J.R., Keck, P.E., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Nemeth, G., Durgam, S. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry (in press)
6. D.I. Cho, M. Zheng, and K.M. Kim Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors Arch. Pharm. Res. 33 2010 1521 1538
7. S. Durgam, A. Starace, D. Li, R. Migliore, A. Ruth, G. Nemeth, and I. Laszlovszky The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial Bipolar Disord. 2014 http://dx.doi.org/10.1111/bdi.12238
8. Y. Gao, S. Peterson, B. Masri, T.M. Hougland, N. Adham, I. Gyertyán, B. Kiss, M.G. Caron, and R.S. El-Mallakh Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor ß-arrestin interactions Pharma Res Per. 2014 http://dx.doi.org/10.1002/prp2.73 (e-pub)
9. A. Graff-Guerrero, D. Mamo, C.M. Shammi, R. Mizrahi, H. Marcon, P. Barsoum, P. Rusjan, S. Houle, A.A. Wilson, and S. Kapur The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO Arch. Gen. Psychiatry 66 2009 606 615
10. G. Gross, and K. Drescher The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions Handbook of Experimental Pharmacology 2012 167 210
11. W. Guy The abnormal movement scale ECDEU Assessment Manual for Psychopharmacology 1976 National Institute of Mental Health Rockville, MD 218 222 (DHEW Publication no.76-338)
12. W. Guy The clinician global severity and impression scales ECDEU Assessment Manual for Psychopharmacology 1976 National Institute of Mental Health Rockville, MD 218 222 (DHEW Publication no.76-338)
13. P.E. Harrison-Read Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors - a new analysis of data from the archives and implications for improved antimanic treatments J. Psychopharmacol. 23 2009 899 907
14. W.D. Johnson, and W.L. May Combining 2×2 tables that contain structural zeros Stat. Med. 14 1995 1901 1911
15. J.N. Joyce, and M.J. Millan Dopamine D3 receptor antagonists as therapeutic agents Drug Discov. Today 10 2005 917 925
16. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
17. M.G. Kenward, G. Molenberghs, and H. Thijs Pattern-mixture models with proper time dependence Biometrika 90 2003 53 71
18. B. Kiss, F. Horti, and A. Bobok Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics Schizophr. Res. 136 suppl 1 2012 S190
19. B. Kiss, A. Horvath, Z. Némethy, E. Schmidt, I. Laszlovszky, G. Bugovics, K. Fazekas, K. Hornok, S. Orosz, I. Gyertyán, E. Ágai-Csongor, G. Domány, K. Tihanyi, N. Adham, and Z. Szombathelyi Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile J. Pharmacol. Exp. Ther. 333 2010 328 340
20. W.K. Kroeze, S.J. Hufeisen, B.A. Popadak, S.M. Renock, S. Steinberg, P. Ernsberger, K. Jayathilake, H.Y. Meltzer, and B.L. Roth H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs Neuropsychopharmacology 28 2003 519 526
21. J. Laszy, I. Laszlovszky, and I. Gyertyán Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats Psychopharmacology (Berlin) 179 2005 567 575
22. G.M. Leggio, S. Salomone, C. Bucolo, C. Platania, V. Micale, F. Caraci, and F. Drago Dopamine D3 receptor as a new pharmacological target for the treatment of depression Eur. J. Pharmacol. 719 2013 25 33
23. J.Y. Leung, A.M. Barr, R.M. Procyshyn, W.G. Honer, and C.C. Pang Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system Pharmacol. Ther. 135 2012 113 122
24. P.N. McCormick, S. Kapur, A. Graff-Guerrero, R. Raymond, J.N. Nobrega, and A.A. Wilson The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective exvivo but not invitro Neuropsychopharmacology 35 2010 1826 1835
25. C.R. Mehta, N.R. Patel, and A.A. Tsiatis Exact significance testing to establish treatment equivalence with ordered categorical data Biometrics 40 1984 819 825
26. R. Mizrahi, O. Agid, C. Borlido, I. Suridjan, P. Rusjan, S. Houle, G. Remington, A.A. Wilson, and S. Kapur Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO Schizophr. Res. 131 2011 63 68
27. S.A. Montgomery, and M. Åsberg A new depression scale designed to be sensitive to change Br. J. Psychiatry 134 1979 382 389
28. K. Posner, G.K. Brown, B. Stanley, D.A. Brent, K.V. Yershova, M.A. Oquendo, G.W. Currier, G.A. Melvin, L. Greenhill, S. Shen, and J.J. Mann The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults Am. J. Psychiatry 168 2011 1266 1277
29. E. Richelson New antipsychotic drugs: how do their receptor-binding profiles compare? J. Clin. Psychiatry 71 2010 1243 1244
30. G.S. Sachs, J.M. Dupuy, and C.W. Wittmann The pharmacologic treatment of bipolar disorder J. Clin. Psychiatry 72 2011 704 715
31. G.S. Sachs, and A.J. Rush Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals? J. Clin. Psychiatry 64 suppl 6 2003 S18 S22 (discussion 28)
32. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side effects Acta Psychiatr. Scand. Suppl. 212 1970 11 19
33. S. Stahl Desribing an Atypical antipsychotic: receptor binding and its role in pathophysiology Prim. Care Companion J. Clin. Psychiatry 5 suppl 3 2003 S9 S13
34. J.M. Tamayo, C.A. Zarate Jr., E. Vieta, G. Vazquez, and M. Tohen Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis Int. J. Neuropsychopharmacol. 13 2010 813 832
35. L.H. Tecott, L.M. Sun, S.F. Akana, A.M. Strack, D.H. Lowenstein, M.F. Dallman, and D. Julius Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors Nature 374 1995 542 546
36. A. Yildiz, E. Vieta, S. Leucht, and R.J. Baldessarini Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials Neuropsychopharmacology 36 2011 375 389
37. R.C. Young, J.T. Biggs, V.E. Ziegler, and D.A. Meyer A rating scale for mania: reliability, validity and sensitivity Br. J. Psychiatry 133 1978 429 435